Literature DB >> 19302924

A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro.

Suganthini Krishnan-Natesan1, Elias K Manavathu, George J Alangaden, Pranatharthi H Chandrasekar.   

Abstract

Zygomycoses is a rapidly progressive infection associated with high mortality. Although amphotericin B (AMB) has been the only treatment option for years, recent studies have demonstrated that posaconazole (PCZ) has good activity against Zygomycetes. Because rapid onset of antifungal activity is crucial in the management and never studied before, we compared the time for maximum fungicidal activity of AMB versus PCZ using time-kill curves. The MIC of AMB and PCZ against clinical isolates of Mucor spp. and Rhizopus spp. was determined by the Clinical and Laboratory Standards Institute M38-A2 method, and the fungicidal activity was examined by time-kill studies. AMB was rapidly fungicidal, with 95% killing noted as early as 6 h and 99.9% killing at 24 h; PCZ showed <70% killing at 6 h and 99.9% killing at 48 h. In vivo animal studies using AMB in the early phase, followed by a switch to high-dose PCZ later, could provide data that may have clinical implications because there are only a few drugs currently available for the management of zygomycoses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302924     DOI: 10.1016/j.diagmicrobio.2008.12.013

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

1.  Lichtheimia corymbifera Colonization Leading to Pulmonary Infection Can Be Prevented with Liposomal Amphotericin B in a New Murine Model.

Authors:  Thomas Brunet; Kévin Brunet; Grégory Jouvion; Estelle Cateau; Sandrine Marchand; Blandine Rammaert
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

3.  Multimodal surgical and medical treatment for extensive rhinocerebral mucormycosis in an elderly diabetic patient: a case report and literature review.

Authors:  Paola Di Carlo; Roberto Pirrello; Giuliana Guadagnino; Pierina Richiusa; Antonio Lo Casto; Caterina Sarno; Francesco Moschella; Daniela Cabibi
Journal:  Case Rep Med       Date:  2014-05-27

4.  Posaconazole treatment in Korea: single-center experience over 5 years.

Authors:  Hyo-Jin Lee; Jae-Cheol Kwon; Si-Hyun Kim; Su-Mi Choi; Dong-Gun Lee; Sun-Hee Park; Jung-Hyun Choi; Jin-Hong Yoo; Byung-Sik Cho; Seok Lee; Hee-Je Kim; Chang-Ki Min; Jong-Wook Lee; Woo-Sung Min
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.